TY - JOUR
T1 - Surgical treatment of liver metastasis of gastric cancer
T2 - a retrospective multicenter cohort study (KSCC1302)
AU - Oki, Eiji
AU - Tokunaga, Shoji
AU - Emi, Yasunori
AU - Kusumoto, Tetsuya
AU - Yamamoto, Manabu
AU - Fukuzawa, Kengo
AU - Takahashi, Ikuo
AU - Ishigami, Sumiya
AU - Tsuji, Akihito
AU - Higashi, Hidefumi
AU - Nakamura, Toshihiko
AU - Saeki, Hiroshi
AU - Shirabe, Ken
AU - Kakeji, Yoshihiro
AU - Sakai, Kenji
AU - Baba, Hideo
AU - Nishimaki, Tadashi
AU - Natsugoe, Shoji
AU - Maehara, Yoshihiko
N1 - Publisher Copyright:
© 2015, The International Gastric Cancer Association and The Japanese Gastric Cancer Association.
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Background: The necessity of surgical treatment of liver metastases of gastric cancer is still controversial. Patients and methods: We conducted a multicenter retrospective cohort study of liver-limited metastasis of gastric cancer treated surgically between 2000 and 2010. In this study, 103 patients were registered, with nine patients excluded from the analysis as they did not meet the eligibility criteria. Results: Of the 94 patients, 69 underwent surgical resection, 11 underwent surgical resection combined with radiofrequency ablation or microwave coagulation therapy for small or deep tumors, and 14 underwent radiofrequency ablation or microwave coagulation therapy only. Synchronous and metachronous metastases were found in 37 and 57 patients, respectively. The 3- and 5-year overall survival rates of all the patients were 51.4 and 42.3 %, respectively. The 3- and 5-year relapse-free survival rates were 29.2 and 27.7 %, respectively. No significant difference in prognosis was observed between the patients who underwent surgical resection and those who underwent ablation therapy. The patients with hepatic solitary lesions and low-grade lymph node metastases of primary gastric cancer had significantly better overall survival and relapse-free survival. Conclusions: To our knowledge, this study is the largest series and first multicenter cohort study of liver-limited metastasis of gastric cancer. The study indicated that patients with a single liver metastasis with a grade lower than N2 lymph node metastasis of the primary lesion are the best candidates for liver resection.
AB - Background: The necessity of surgical treatment of liver metastases of gastric cancer is still controversial. Patients and methods: We conducted a multicenter retrospective cohort study of liver-limited metastasis of gastric cancer treated surgically between 2000 and 2010. In this study, 103 patients were registered, with nine patients excluded from the analysis as they did not meet the eligibility criteria. Results: Of the 94 patients, 69 underwent surgical resection, 11 underwent surgical resection combined with radiofrequency ablation or microwave coagulation therapy for small or deep tumors, and 14 underwent radiofrequency ablation or microwave coagulation therapy only. Synchronous and metachronous metastases were found in 37 and 57 patients, respectively. The 3- and 5-year overall survival rates of all the patients were 51.4 and 42.3 %, respectively. The 3- and 5-year relapse-free survival rates were 29.2 and 27.7 %, respectively. No significant difference in prognosis was observed between the patients who underwent surgical resection and those who underwent ablation therapy. The patients with hepatic solitary lesions and low-grade lymph node metastases of primary gastric cancer had significantly better overall survival and relapse-free survival. Conclusions: To our knowledge, this study is the largest series and first multicenter cohort study of liver-limited metastasis of gastric cancer. The study indicated that patients with a single liver metastasis with a grade lower than N2 lymph node metastasis of the primary lesion are the best candidates for liver resection.
UR - http://www.scopus.com/inward/record.url?scp=84938903569&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84938903569&partnerID=8YFLogxK
U2 - 10.1007/s10120-015-0530-z
DO - 10.1007/s10120-015-0530-z
M3 - Article
C2 - 26260876
AN - SCOPUS:84938903569
SN - 1436-3291
VL - 19
SP - 968
EP - 976
JO - Gastric Cancer
JF - Gastric Cancer
IS - 3
ER -